Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Evaluation of Clinical Risk Factors and Thrombosis-Related Biomarkers in Newly Diagnosed Patients with Multiple Myeloma at Risk for Cancer-Associated Thrombosis. the Observational Roadmat-CAT-MM Study

Patrick Van Dreden, Loula Papageorgiou, Eleftheria Lefkou, Despina Fotiou, Efstathios Kastritis, Evangelos Terpos, Aurelie Rousseau, Michele Sabbah, Matthieu Grusse, Ismail Elalamy, Elisabeth Mbemba, Meletios Athanasios Dimopoulos, Grigoris Gerotziafas

Blood (2023) 142 (Supplement 1): 5404.

https://doi.org/10.1182/blood-2023-187055

Published: 2023

Journal Articles

Prothrombotic Profile in Patients with Active Multiple Myeloma and the Impact of Immunomodulators: The Roadmap-MM Study

Patrick Van Dreden, Loula Papageorgiou, Eleftheria Lefkou, Despina Fotiou, Efstathios Kastritis, Evangelos Terpos, Aurelie Rousseau, Michele Sabbah, Matthieu Grusse, Elisabeth Mbemba, Ismail Elalamy, Meletios Athanasios Dimopoulos, Grigoris Gerotziafas

Blood (2023) 142 (Supplement 1): 1203.

https://doi.org/10.1182/blood-2023-186645

Published: 2023

Journal Articles

Analysis of Inter-Observer Agreement of Adjudication of Colors of Pad Colors of Doac Dipstick to Determine Presence or Absence of Direct Oral Anticoagulants in Outpatients' Urine Samples

Loula Papageorgiou, Job Harenberg, Ismail Elalamy, Grigoris Gerotziafas

Blood (2021) 138 (Supplement 1): 3213.

https://doi.org/10.1182/blood-2021-149461

Published: 2021

Journal Articles

Stratification of Vascular Profile in Multiple Myeloma Patients Using Thrombin Generation Test

Loula Papageorgiou, Patrick Van Dreden, PhD, Laurent Garderet, MD PhD, Matthieu Grusse, Ismail Elalamy, MD PhD, Grigoris Gerotziafas, MD PhD

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-139424

Published: 2020

Journal Articles

Biomarkers of Hypercoagulability and Endothelial Cell Activation in Patients with Severe COVID-19 Admitted at the Intensive Care Unit. the Roadmap-COVID-19 Prospective Observational Study

Patrick Van Dreden, PhD, Guillaume Voiriot, Alexandre Alabbadi, Ismail Elalamy, MD PhD, Loula Papageorgiou, Hélène Cost, Aurélie Rousseau, PhD, Matthieu Turpin, Muriel Fartoukh, Grigorios T. Gerotziafas

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-140275

Published: 2020

Journal Articles

Derivation and Validation of a Predictive Score for Disease Worsening Inpatients with COVID-19

Grigoris Gerotziafas, MD PhD, Patrick Van Dreden, PhD, Loula Papageorgiou, Theodoros N Sergentanis, MD PhD, Meletios-Athanasios Dimopoulos, Ismail Elalamy, MD PhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-136528

Published: 2020

Journal Articles

Hypercoagulability Biomarkers in a New Score Linked to Treatment Resistance for Multiple Myeloma Patients. the Roadmap-MM Study

Loula Papageorgiou, Despina Fotiou, BMBS, MA, Patrick Van Dreden, PhD, Laurent Garderet, MD PhD, Meletios A. Dimopoulos, MD, Ismail Elalamy, MD PhD, Mohamad Mohty, MD PhD, Grigoris Gerotziafas, MD PhD

Blood (2019) 134 (Supplement_1): 1913.

https://doi.org/10.1182/blood-2019-126954

Published: 2019

Journal Articles

Procoagulant Microparticles Derived from Myeloma Plasma Cells Have a Determinant Role in the Hypercoagulable State Associated with Multiple Myeloma. a Modelization in Vitro Study

Loula Papageorgiou, Patrick Van Dreden, PhD, Meletios A. Dimopoulos, MD, Annette Larsen, Mohamad Mohty, MD PhD, Ismail Elalamy, MD PhD, Grigorios T. Gerotziafas

Blood (2019) 134 (Supplement_1): 2425.

https://doi.org/10.1182/blood-2019-124650

Published: 2019

Journal Articles

In Newly Diagnosed Multiple Myeloma Patients, Longer Procoagulant Phospholipid-Dependent Clotting Time, Higher Levels of P-Selectin, D-Dimers and Thrombin Generation Peak Are Associated with Increased Risk of Resistance to Treatment: Results of the Prospective Roadmap-MM Study

Grigorios T. Gerotziafas, Despina Fotiou, BMBS, MA, Patrick Van Dreden, PhD, Theodoros N Sergentanis, Ismail Elalamy, MD PhD, Loula Papageorgiou, Matthieu Grusse, Stella Salta, Theodora Psaltopoulou, Annette Larsen, Evangelos Terpos, MD PhD, Meletios A Dimopoulos, MD

Blood (2018) 132 (Supplement 1): 2014.

https://doi.org/10.1182/blood-2018-99-114871

Published: 2018

Journal Articles

Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer Associated Thrombosis. the Observational Roadmap-CAT Study

Grigorios T. Gerotziafas, MD PhD, Patrick Van Dreden, PhD, Stella Salta, Loula Papageorgiou, Paraskevi Boura, Annette Larsen, Jawed Fareed, PhD, Konstantinos Syrigos, Ismail Elalamy, MD PhD

Blood (2017) 130 (Supplement 1): 2381.

https://doi.org/10.1182/blood.V130.Suppl_1.2381.2381

Published: 2017

Journal Articles

An Ex Vivo Analysis of Thrombin Generation and Thromboelastometry in Patients Undergoing Treatment with Rivaroxaban Demonstrates Sustained Anticoagulant Effect and High Inter-Individual Variability

Stella Salta, Patrick Van Dreden, PhD, Loula Papageorgiou, Jawed Fareed, PhD, Ismail Elalamy, MD PhD, Grigorios T. Gerotziafas, MD PhD

Blood (2017) 130 (Supplement 1): 3722.

https://doi.org/10.1182/blood.V130.Suppl_1.3722.3722

Published: 2017

Journal Articles

Alteration of Endothelial Cell Hemostatic Equilibrium By Cancer Cell-Derived Microparticles, a New Insight in Pathogenesis of Cancer Associated Thrombosis

Aurélie Rousseau, PhD, Rania Amrane, Patrick Van Dreden, PhD, Loula Papageorgiou, Annette Larsen, Amir Khaterchi, Ismail Elalamy, MD PhD, Grigorios T. Gerotziafas, MD PhD

Blood (2017) 130 (Supplement 1): 3698.

https://doi.org/10.1182/blood.V130.Suppl_1.3698.3698

Published: 2017

Journal Articles

Defining the Balance between the Expression of Procoagulant, Anticoagulant and Angiogenic Molecules in Myeloma Plasma Cells

Loula Papageorgiou, Sandrine Thouronde, Patrick Van Dreden, PhD, Stella Salta, Laurent Garderet, MD PhD, Christelle Mazurier, Ismail Elalamy, MD PhD, Grigorios T. Gerotziafas, MD PhD

Blood (2017) 130 (Supplement 1): 5364.

https://doi.org/10.1182/blood.V130.Suppl_1.5364.5364

Published: 2017

Journal Articles

Procoagulant Phospholipid Dependent Clotting Time: A New Tool for the Identification of Multiple Myeloma Patients at Risk Poor Treatment Response

Fotiou Despina, Loula Papageorgiou, Stella Salta, Patrick Van Dreden, PhD, Evangelos Terpos, Jawed Fareed, PhD, Matthieu Grusse, Ismail Elalamy, MD PhD, Laurent Garderet, MD PhD, Christelle Mazurier, Grigorios T. Gerotziafas, MD PhD

Blood (2017) 130 (Supplement 1): 1110.

https://doi.org/10.1182/blood.V130.Suppl_1.1110.1110

Published: 2017

Journal Articles

Presence Of CD55- and/Or CD59-Deficient Erythrocytes In Patients With Rheumatic Diseases: An Immune-Mediated Phenomenon?

John V. Asimakopoulos, Evangelos Terpos, Loula Papageorgiou, Olga Kampouropoulou, Dimitrios Christoulas, Anastasios Giakoumis, George Vaiopoulos, Kostas Konstantopoulos, Maria K. Angelopoulou, Theodoros P. Vassilakopoulos, John Meletis

Blood (2013) 122 (21): 3429.

https://doi.org/10.1182/blood.V122.21.3429.3429

Published: 2013

NARROW

Evaluation of Clinical Risk Factors and Thrombosis-Related Biomarkers in Newly Diagnosed Patients with Multiple Myeloma at Risk for Cancer-Associated Thrombosis. the Observational Roadmat-CAT-MM Study

Prothrombotic Profile in Patients with Active Multiple Myeloma and the Impact of Immunomodulators: The Roadmap-MM Study

Analysis of Inter-Observer Agreement of Adjudication of Colors of Pad Colors of Doac Dipstick to Determine Presence or Absence of Direct Oral Anticoagulants in Outpatients' Urine Samples

Stratification of Vascular Profile in Multiple Myeloma Patients Using Thrombin Generation Test

Biomarkers of Hypercoagulability and Endothelial Cell Activation in Patients with Severe COVID-19 Admitted at the Intensive Care Unit. the Roadmap-COVID-19 Prospective Observational Study

Derivation and Validation of a Predictive Score for Disease Worsening Inpatients with COVID-19

Hypercoagulability Biomarkers in a New Score Linked to Treatment Resistance for Multiple Myeloma Patients. the Roadmap-MM Study

Procoagulant Microparticles Derived from Myeloma Plasma Cells Have a Determinant Role in the Hypercoagulable State Associated with Multiple Myeloma. a Modelization in Vitro Study

In Newly Diagnosed Multiple Myeloma Patients, Longer Procoagulant Phospholipid-Dependent Clotting Time, Higher Levels of P-Selectin, D-Dimers and Thrombin Generation Peak Are Associated with Increased Risk of Resistance to Treatment: Results of the Prospective Roadmap-MM Study

Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer Associated Thrombosis. the Observational Roadmap-CAT Study

An Ex Vivo Analysis of Thrombin Generation and Thromboelastometry in Patients Undergoing Treatment with Rivaroxaban Demonstrates Sustained Anticoagulant Effect and High Inter-Individual Variability

Alteration of Endothelial Cell Hemostatic Equilibrium By Cancer Cell-Derived Microparticles, a New Insight in Pathogenesis of Cancer Associated Thrombosis

Defining the Balance between the Expression of Procoagulant, Anticoagulant and Angiogenic Molecules in Myeloma Plasma Cells

Procoagulant Phospholipid Dependent Clotting Time: A New Tool for the Identification of Multiple Myeloma Patients at Risk Poor Treatment Response

Presence Of CD55- and/Or CD59-Deficient Erythrocytes In Patients With Rheumatic Diseases: An Immune-Mediated Phenomenon?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only